<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients receiving recurring blood transfusions as supportive therapy to treat <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001903'>anemias</z:hpo>, such as <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e>, and <z:e sem="disease" ids="C0002895" disease_type="Disease or Syndrome" abbrv="">sickle-cell disease</z:e>, are at risk of iron accumulation </plain></SENT>
<SENT sid="1" pm="."><plain>The clinical consequences of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> are progressive liver damage, <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e>, and <z:chebi fb="32" ids="24621">endocrine</z:chebi> disorders, which can be fatal </plain></SENT>
<SENT sid="2" pm="."><plain>Nurses have a vital role in the initial assessment and monitoring of patients undergoing transfusion therapy and their ongoing care </plain></SENT>
<SENT sid="3" pm="."><plain>Iron levels may be managed effectively with iron chelation therapy, and treatment guidelines recommend initiation when serum ferritin levels reach more than 1,000 mcg/L </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="4356">Deferoxamine</z:chebi> has been used effectively in clinical practice for more than 40 years </plain></SENT>
<SENT sid="5" pm="."><plain>Newer agents, such as <z:chebi fb="0" ids="49005">deferasirox</z:chebi>, have introduced the option of oral therapy to manage <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Those agents and practical management of patients receiving multiple blood transfusions are discussed </plain></SENT>
</text></document>